Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib with Cisplatin and Docetaxel in SCCHN
NCT02035527Phase 1Completed
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Apr 2014
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sorafenib in squamous cell carcinoma of the head and neck (HNSCC), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Primary endpoints: Incidence of Dose-Limiting Toxicity and Progression-Free Survival. Started Apr 2014; status: completed.
02
Drugs
sorafenib
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02035527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02035527.